Type I interferon gene signature test–low and –high patients with systemic lupus erythematosus have distinct gene expression signatures

Abstract

Objectives

Type I interferon (IFN) is implicated in systemic lupus erythematosus (SLE) pathogenesis. We aimed to identify type I IFN signaling-dependent and -independent molecular pathways in a large population of patients with SLE.

Methods

Baseline blood samples from adult patients with moderate to severe SLE from two Phase IIb studies (NCT01438489, n = 265; NCT01283139, n = 416) were profiled using whole transcriptome array analyses. Type I IFN gene signature (IFNGS) test status (high or low) was determined using a validated qualitative polymerase chain reaction–based test. IFN-type-specific signatures were developed by stimulating healthy blood with IFN-β, IFN-γ, IFN-λ, IFN-ω, or pooled IFN-α. These, and multiple literature-derived cell type and cytokine pathway signatures, were evaluated in individual and pooled study populations. A Fisher’s exact test was used for associations, adjusted for false discovery rate.

Results

Whole blood samples from IFNGS test–high patients were enriched versus IFNGS test–low patients for CD40L signaling (Q < 0.001), CXC cytokine (Q < 0.001), TLR8-mediated monocyte activation (Q < 0.001), IgG (Q < 0.001), major histocompatibility complex class I (Q < 0.001), and plasma cell (Q < 0.001) gene expression signatures. IFNGS test–low patients had significant enrichment of eosinophil (Q < 0.001), IFN-γ-specific (Q = 0.005), and T-cell or B-cell (Q < 0.001) signatures. Similar enrichment profiles were demonstrated in patients with primary Sjögren’s syndrome, systemic sclerosis, and dermatomyositis.

Conclusions

IFNGS test–high patients overexpressed many gene signatures associated with SLE pathogenesis compared with IFNGS test–low patients, reflecting broad immune activation. These results provide new insights into the molecular heterogeneity underlying SLE pathogenesis, highlighting shared mechanisms beyond type I IFN, across several autoimmune diseases.

Trial registration

Clinicaltrials.gov: NCT01438489 and NCT01283139.

Keywords

Anifrolumab disease pathogenesis type I IFN systemic lupus erythematosus transcriptomics

Get full access to this article

View all access options for this article.

References

Oon

Wilson

Wicks

. Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway. Clin Transl Immunology 2016; 5: e79–e79.

Ippolito

Wallace

Gladman

, et al. Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity. Lupus 2011; 20: 250–255.

Cozzani

Drosera

Gasparini

Parodi

. Serology of lupus erythematosus: correlation between immunopathological features and clinical aspects. Autoimmune Dis 2014; 2014: 321359–321359.

Baechler

Batliwalla

Karypis

, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100: 2610–2615.

Bennett

Palucka

Arce

, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711–723.

Crow

. Advances in understanding the role of type I interferons in systemic lupus erythematosus. Curr Opin Rheumatol 2014; 26: 467–474.

Rönnblom

Alm

Eloranta

. The type I interferon system in the development of lupus. Semin Immunol 2011; 23: 113–121.

Crow

. Type I interferon in the pathogenesis of lupus. J Immunol 2014; 192: 5459–5468.

Munroe

Zhao

, et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis 2016; 75: 2014–2021.

10.

Rönnblom

Eloranta

. The interferon signature in autoimmune diseases. Curr Opin Rheumatol 2013; 25: 248–253.

11.

Elkon

Stone

. Type I interferon and systemic lupus erythematosus. J Interferon Cytokine Res 2011; 31: 803–812.

12.

Guiducci

Coffman

Barrat

. Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. J Intern Med 2009; 265: 43–57.

13.

Furie

Khamashta

Merrill

, et al. Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 2017; 69: 376–386.

14.

Yao

Richman

Higgs

, et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1785–1796.

15.

Khamashta

Merrill

Werth

, et al. Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016; 75: 1909–1916.

16.

Yao

Higgs

Morehouse

, et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-alpha monoclonal antibody trials in systemic lupus erythematosus. Hum Genomics Proteomics 2009; 2009: pii: 374312–pii: 374312.

17.

American College of Rheumatology. 1997 update of the 1982 American College of Rheumatology revised criteria for classification of systemic lupus erythematosus, https://www.rheumatology.org/Portals/0/Files/1997%20Update%20of%201982%20Revised.pdf (1997, accessed 8 September 2017).

18.

Yao

Higgs

Richman

, et al. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNalpha antibody, in systemic lupus erythematosus. Arthritis Res Ther 2010; 12(Suppl. 1): S6–S6.

19.

Yao

Richman

Morehouse

, et al.

Type I interferon: potential therapeutic target for psoriasis?

PLoS One 2008; 3: e2737–e2737.

20.

Hanzelmann

Castelo Guinney

. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 2013; 14: 7–7.

21.

Streicher

Sridhar

Kuziora

, et al. Baseline plasma cell gene signature predicts improvement in systemic sclerosis skin scores following treatment with inebilizumab (MEDI-551) and correlates with disease activity in systemic lupus erythematosus and chronic obstructive pulmonary disease. Arthritis Rheumatol 2018; 70: 2087–2095.

22.

Sarin

Chung

Kim

, et al. Molecular profiling to diagnose a case of atypical dermatomyositis. J Invest Dermatol 2013; 133: 2796–2799.

23.

Higgs

Zhu

Morehouse

, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 2014; 73: 256–262.

24.

Zhu

Streicher

Shen

, et al. Genomic signatures characterize leukocyte infiltration in myositis muscles. BMC Med Genomics 2012; 5: 53–53.

25.

Higgs

Zhu

Richman

, et al. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients. Int J Rheum Dis 2012; 15: 25–35.

26.

Wong

Kea

Pesich

, et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One 2012; 7: e29161–e29161.

27.

Greenberg

Higgs

Morehouse

, et al. Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun 2012; 13: 207–213.

28.

Higgs

Liu

White

, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011; 70: 2029–2036.

29.

James

Al-Ali

Tarn

, et al. A transcriptional signature of fatigue derived from patients with primary Sjogren’s syndrome. PLoS One 2015; 10: e0143970–e0143970.

30.

Streicher

Morehouse

Groves

, et al. The plasma cell signature in autoimmune disease. Arthritis Rheumatol 2014; 66: 173–184.

31.

Yao

Liu

Jallal

, et al. Type I interferons in Sjogren’s syndrome. Autoimmun Rev 2013; 12: 558–566.

32.

Becker

Dao

Han

, et al. SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature. PLoS One 2013; 8: e67003–e67003.

33.

Waddell

Popper

Rubins

, et al. Dissecting interferon-induced transcriptional programs in human peripheral blood cells. PLoS One 2010; 5: e9753–e9753.

34.

Cheng

, et al. Type I interferons suppress viral replication but contribute to T cell depletion and dysfunction during chronic HIV-1 infection. JCI Insight 2017; 2: pii: 94366–pii: 94366.

35.

Golding

Rosen

Petri

, et al. Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses. Immunology 2010; 131: 107–117.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.37 MB